Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.65 USD

85.65
493,550

+2.10 (2.51%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $85.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Zacks Equity Research

PDCO or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Zacks Equity Research

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

by Zacks Equity Research

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.

Zacks Equity Research

Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Inspire Medical's (INSP) global presence.

Zacks Equity Research

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

by Zacks Equity Research

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Zacks Equity Research

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Zacks Equity Research

Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.

Zacks Equity Research

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

by Zacks Equity Research

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Zacks Equity Research

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

by Zacks Equity Research

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

by Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Zacks Equity Research

Masimo's (MASI) Launch to Serve the Personalized Hearables Market

by Zacks Equity Research

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Equity Research

Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.

Zacks Equity Research

QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod

by Zacks Equity Research

QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Zacks Equity Research

Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering

by Zacks Equity Research

Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.

Zacks Equity Research

Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe

by Zacks Equity Research

Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.

Zacks Equity Research

3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Zacks Equity Research

PacBio's (PACB) New Tie-Up to Boost Rare Disease Research

by Zacks Equity Research

PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.

Zacks Equity Research

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

by Zacks Equity Research

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.

Zacks Equity Research

Quest Diagnostics (DGX) Partners to Offer New Testing Service

by Zacks Equity Research

Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.